Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 18;5(5):CD002190.
doi: 10.1002/14651858.CD002190.pub5.

Vaccines for the common cold

Daniel Simancas-Racines  1 , Juan Va Franco  2 , Claudia V Guerra  3 , Maria L Felix  4 , Ricardo Hidalgo  3 , Maria José Martinez-Zapata  5   6
Affiliations

Vaccines for the common cold

Daniel Simancas-Racines et al. Cochrane Database Syst Rev. .

Update in

  • Vaccines for the common cold.
    Montesinos-Guevara C, Buitrago-Garcia D, Felix ML, Guerra CV, Hidalgo R, Martinez-Zapata MJ, Simancas-Racines D. Montesinos-Guevara C, et al. Cochrane Database Syst Rev. 2022 Dec 14;12(12):CD002190. doi: 10.1002/14651858.CD002190.pub6. Cochrane Database Syst Rev. 2022. PMID: 36515550 Free PMC article.

Abstract

Background: The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, sneezing, cough, malaise, sore throat, and fever (usually < 37.8º C). The widespread morbidity caused by the common cold worldwide is related to its ubiquitousness rather than its severity. The development of vaccines for the common cold has been difficult because of antigenic variability of the common cold virus and the indistinguishable multiple other viruses and even bacteria acting as infective agents. There is uncertainty regarding the efficacy and safety of interventions for preventing the common cold in healthy people. This is an update of a Cochrane review first published in 2011 and previously updated in 2013.

Objectives: To assess the clinical effectiveness and safety of vaccines for preventing the common cold in healthy people.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (September 2016), MEDLINE (1948 to September 2016), Embase (1974 to September 2016), CINAHL (1981 to September 2016), and LILACS (1982 to September 2016). We also searched three trials registers for ongoing studies and four websites for additional trials (February 2017). We included no language or date restrictions.

Selection criteria: Randomised controlled trials (RCTs) of any virus vaccines compared with placebo to prevent the common cold in healthy people.

Data collection and analysis: Two review authors independently evaluated methodological quality and extracted trial data. We resolved disagreements by discussion or by consulting a third review author.

Main results: We found no additional RCTs for inclusion in this update. This review includes one RCT dating from the 1960s with an overall high risk of bias. The RCT included 2307 healthy participants, all of whom were included in analyses. This trial compared the effect of an adenovirus vaccine against placebo. No statistically significant difference in common cold incidence was found: there were 13 (1.14%) events in 1139 participants in the vaccines group and 14 (1.19%) events in 1168 participants in the placebo group (risk ratio 0.95, 95% confidence interval 0.45 to 2.02; P = 0.90). No adverse events related to the live vaccine were reported. The quality of the evidence was low due to limitations in methodological quality and a wide 95% confidence interval.

Authors' conclusions: This Cochrane Review was based on one study with low-quality evidence. We found no conclusive results to support the use of vaccines for preventing the common cold in healthy people compared with placebo. We identified a need for well-designed, adequately powered RCTs to investigate vaccines for the common cold in healthy people. Any future trials on medical treatments for preventing the common cold should assess a variety of virus vaccines for this condition. Outcome measures should include common cold incidence, vaccine safety, and mortality related to the vaccine.

PubMed Disclaimer

Conflict of interest statement

Daniel Simancas‐Racines: None known. Juan VA Franco: None known. Claudia V Guerra: None known. Maria L Felix: None known. Ricardo Hidalgo: None known. Maria José Martinez‐Zapata: None known.

Figures

1
1
Study flow diagram
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
3
3
'Risk of bias' summary: review authors' judgements about each risk of bias item for the included study
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Griffin 1970 {published data only}
    1. Griffin JP, Greenberg BH. Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine 1970;125(6):981‐6. [PUBMED: 4378136] - PubMed

References to studies excluded from this review

Belshe 1982 {published data only}
    1. Belshe RB, Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. Journal of Infectious Diseases 1982;145(3):311‐9. [PUBMED: 7037983] - PubMed
Belshe 1992 {published data only}
    1. Belshe RB, Karron RA, Newman FK, Anderson EL, Nugent SL, Steinhoff M, et al. Evaluation of a live attenuated, cold‐adapted parainfluenza virus type 3 vaccine in children. Journal of Clinical Microbiology 1992;30(8):2064‐70. [PUBMED: 1323576] - PMC - PubMed
Belshe 2004a {published data only}
    1. Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. Journal of Infectious Diseases 2004;190(12):2096‐103. [PUBMED: 15551207] - PubMed
Belshe 2004b {published data only}
    1. Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6‐18 months old. Journal of Infectious Diseases 2004;189(3):462‐70. [PUBMED: 14745704] - PubMed
Clements 1991 {published data only}
    1. Clements ML, Belshe RB, King J, Newman F, Westblom TU, Tierney EL, et al. Evaluation of bovine, cold‐adapted human, and wild‐type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. Journal of Clinical Microbiology 1991;29(6):1175‐82. [PUBMED: 1650789] - PMC - PubMed
DeVincenzo 2010 {published data only}
    1. DeVincenzo J, Lambkin‐Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, et al. A randomized, double‐blind, placebo‐controlled study of an RNAi‐based therapy directed against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America 2010;107(19):8800‐5. [PUBMED: 20421463] - PMC - PubMed
Doggett 1963 {published data only}
    1. Doggett JE, Bynoe ML, Tyrrell DA. Some attempts to produce an experimental vaccine with rhinoviruses. British Medical Journal 1963;1(5322):34‐6. [PUBMED: 14028369] - PMC - PubMed
Dudding 1972 {published data only}
    1. Dudding BA, Bartelloni PJ, Scott RM, Top FH Jr, Russell PK, Buescher EL. Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers. Infection and Immunity 1972;5(3):295‐9. [PUBMED: 4564559] - PMC - PubMed
Falsey 1996 {published data only}
    1. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP‐2) in ambulatory adults over age 60. Vaccine 1996;14(13):1214‐8. [PUBMED: 8961507] - PubMed
Falsey 2008 {published data only}
    1. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines ‐ nonadjuvanted vaccine or vaccine adjuvanted with alum ‐ given concomitantly with influenza vaccine to high‐risk elderly individuals. Journal of Infectious Diseases 2008;198(9):1317‐26. [PUBMED: 18855558] - PubMed
Fulginiti 1969 {published data only}
    1. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum‐precipitated respiratory syncytial virus vaccine. American Journal of Epidemiology 1969;89(4):435‐48. [PUBMED: 4305199] - PubMed
Glenn 2016 {published data only}
    1. Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, et al. A randomized, blinded, controlled, dose‐ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. Journal of Infectious Diseases 2016; Vol. 213, issue 3:411‐22. - PubMed
Gomez 2009 {published data only}
    1. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase‐I study MEDI‐534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza‐3 virus in seropositive children. Pediatric Infectious Disease Journal 2009;28(7):655‐8. [PUBMED: 19483659] - PubMed
Gonzalez 2000 {published data only}
    1. Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP‐2) in healthy young and older adults. Vaccine 2000;18(17):1763‐72. [PUBMED: 10699324] - PubMed
Greenberg 2005 {published data only}
    1. Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. Journal of Infectious Diseases 2005;191(7):1116‐22. [PUBMED: 15747247] - PubMed
Hamory 1975 {published data only}
    1. Hamory BH, Hamparian VV, Conant RM, Gwaltney JM Jr. Human responses to two decavalent rhinovirus vaccines. Journal of Infectious Diseases 1975;132(6):623‐9. [PUBMED: 172561] - PubMed
Karron 1995a {published data only}
    1. Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. Journal of Infectious Diseases 1995;171(5):1107‐14. [PUBMED: 7751684] - PubMed
Karron 1995b {published data only}
    1. Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. Journal of Infectious Diseases 1995;172(6):1445‐50. [PUBMED: 7594701] - PubMed
Karron 1997 {published data only}
    1. Karron RA, Wright PF, Crowe JE Jr, Clements‐Mann ML, Thompson J, Makhene M, et al. Evaluation of two live, cold‐passaged, temperature‐sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. Journal of Infectious Diseases 1997;176(6):1428‐36. [PUBMED: 9395351] - PubMed
Karron 2003 {published data only}
    1. Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatric Infectious Disease Journal 2003;22(5):394‐405. [PUBMED: 12792378] - PubMed
Karron 2005 {published data only}
    1. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. Journal of Infectious Diseases 2005;191(7):1093‐104. [PUBMED: 15747245] - PubMed
Karron 2015 {published data only}
    1. Karron RA, Mateo JS, Thumar B, Schaap‐Nutt A, Buchholz UJ, Schmidt AC, et al. Evaluation of a live‐attenuated human parainfluenza type 1 vaccine in adults and children. Journal of Pediatric Infectious Diseases Society 2015; Vol. 4, issue 4:e143‐6. - PMC - PubMed
Kumpu 2015 {published data only}
    1. Kumpu M, Kekkonen RA, Korpela R, Tynkkynen S, Järvenpää S, Kautiainen H, et al. Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: randomised, double blind, placebo‐controlled pilot trial. Beneficial Microbes 2015; Vol. 6, issue 5:631‐9. - PubMed
Langley 2009 {published data only}
    1. Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, et al. A dose‐ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or = 65 years of age. Vaccine 2009;27(42):5913‐9. [PUBMED: 19651171] - PubMed
Lee 2001 {published data only}
    1. Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI, et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. Journal of Infectious Diseases 2001;184(7):909‐13. [PUBMED: 11509996] - PubMed
Lee 2004 {published data only}
    1. Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Research 2004;63(3):191‐6. [PUBMED: 15451187] - PubMed
Lin 2007 {published data only}
    1. Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antiviral Therapy 2007;12(7):1107‐13. [PUBMED: 18018769] - PubMed
Lyons 2008 {published data only}
    1. Lyons A, Longfield J, Kuschner R, Straight T, Binn L, Seriwatana J, et al. A double‐blind, placebo‐controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008;26(23):2890‐8. [PUBMED: 18448211] - PubMed
Madhi 2006 {published data only}
    1. Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine 2006;24(13):2432‐9. [PUBMED: 16406170] - PubMed
Munoz 2003 {published data only}
    1. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein‐2 vaccine in pregnant women. Vaccine 2003;21(24):3465‐7. [PUBMED: 12850361] - PubMed
Murphy 1994 {published data only}
    1. Murphy BR, Hall SL, Kulkarni AB, Crowe JE Jr, Collins PL, Connors M, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research 1994;32(1):13‐36. [PUBMED: 8030364] - PubMed
Paradiso 1994 {published data only}
    1. Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatric Infectious Disease Journal 1994;13(9):792‐8. [PUBMED: 7808848] - PubMed
Piedra 1995 {published data only}
    1. Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, et al. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 1995;13(12):1095‐101. [PUBMED: 7491817] - PubMed
Pierce 1968 {published data only}
    1. Pierce WE, Rosenbaum MJ, Edwards EA, Peckinpaugh RO, Jackson GG. Live and inactivated adenovirus vaccines for the prevention of acute respiratory illness in naval recruits. American Journal of Epidemiology 1968;87(1):237‐46. [PUBMED: 4295428] - PubMed
Power 2001 {published data only}
    1. Power UF, Nguyen TN, Rietveld E, Swart RL, Groen J, Osterhaus AD, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. Journal of Infectious Diseases 2001;184(11):1456‐60. [PUBMED: 11709789] - PubMed
Ritchie 1958 {published data only}
    1. Ritchie JM. Autogenous vaccine in prophylaxis of the common cold. Lancet 1958;1(7021):615‐8. [PUBMED: 13515297] - PubMed
Simoes 2001 {published data only}
    1. Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 2001;20(5‐6):954‐60. [PUBMED: 11738763] - PubMed
Tang 2008 {published data only}
    1. Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, et al. Development of a PIV‐vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 2008;26(50):6373‐82. [PUBMED: 18822334] - PubMed
Top 1971 {published data only}
    1. Top FH Jr, Buescher EL, Bancroft WH, Russell PK. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. Journal of Infectious Diseases 1971;124(2):155‐60. [PUBMED: 4330998] - PubMed
Tristram 1993 {published data only}
    1. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18‐36 months old. Journal of Infectious Diseases 1993;167(1):191‐5. [PUBMED: 8418166] - PubMed
Watt 1990 {published data only}
    1. Watt PJ, Robinson BS, Pringle CR, Tyrrell DA. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 1990;8(3):231‐6. [PUBMED: 2363300] - PubMed
Welliver 1994 {published data only}
    1. Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S. Respiratory syncytial virus‐specific cell‐mediated immune responses after vaccination with a purified fusion protein subunit vaccine. Journal of Infectious Diseases 1994;170(2):425‐8. [PUBMED: 8035030] - PubMed
Wilson 1960 {published data only}
    1. Wilson JS, Grant PJ, Miller DL, Taylor CE, McDonald JC. Trial of adenovirus vaccine in Royal Air Force recruits. British Medical Journal 1960;1(5179):1081‐3. [PUBMED: 13845090] - PMC - PubMed
Wright 1976 {published data only}
    1. Wright PF, Shinozaki T, Fleet W, Sell SH, Thompson J, Karzon DT. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. Journal of Pediatrics 1976;88(6):931‐6. [PUBMED: 178852] - PubMed

Additional references

Abbas 2001
    1. Abbas A, Lichtman A. Glossary. Basic Immunology. Vol. 1, Philadelphia, PA: WB Saunders Company, 2001.
Adams 1999
    1. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey 1996. Vital Health Statistics 1999;10(200):1‐203. [MEDLINE: ] - PubMed
Altman 1995
    1. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311(7003):485. [PUBMED: 7647644] - PMC - PubMed
Anonymous 2012
    1. Anonymous. Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636‐40. [PUBMED: 22511692] - PubMed
Arruda 1997
    1. Arruda E, Pitkäranta A, Witek TJ Jr, Doyle CA, Hayden FG. Frequency and natural history of rhinovirus infections in adults during autumn. Journal of Clinical Microbiology 1997;35(11):2864‐8. [MEDLINE: ] - PMC - PubMed
Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. - PMC - PubMed
Bembridge 1998
    1. Bembridge G, Garcia‐Beato R, Lòpez J, Melero J, Taylor G. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. Journal of Immunology 1998;161(5):2473‐80. [MEDLINE: ] - PubMed
Berman 1991
    1. Berman S. Epidemiology of acute respiratory infections in children of developing countries. Reviews of Infectious Diseases 1991;13(Suppl 6):454‐62. [MEDLINE: ] - PubMed
Binn 2007
    1. Binn LN, Sanchez JL, Gaydos JC. Emergence of adenovirus type 14 in US military recruits ‐ a new challenge. Journal of Infectious Diseases 2007;196(10):1436‐7. [MEDLINE: ] - PubMed
DDCP 2010
    1. Division of Disease Control and Prevention, Utah Department of Health. Difference between cold and flu symptoms. health.utah.gov/epi/diseases/flu/ColdvsFlu.pdf 2010 (accessed prior to 12 May 2017).
Denny 1983
    1. Denny FW, Murphy TF, Clyde WA, Collier AM, Henderson FW. Croup: an 11 year study in a pediatric practice. Pediatrics 1983;71(6):871‐6. [MEDLINE: ] - PubMed
Edlmayr 2009
    1. Edlmayr J, Niespodziana K, Linhart B, Focke‐Tejk lM, Westrtschnig K, Scheiblhober S, et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus‐derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen PHl p1. Journal of Immunology 2009;182(10):6298‐306. [MEDLINE: ] - PubMed
Eriksson 2006
    1. Eriksson KK, Makia D, Maier R, Ludewig B, Thiel V. Towards a coronavirus‐based HIV multigene vaccine. Clinical and Developmental Immunology 2006;13(2‐4):353‐60. [MEDLINE: ] - PMC - PubMed
Esper 2003
    1. Esper F, Boucher D, Weibel C, Martinello RA, Kahn JS. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics 2003;111(6 pt 1):1407‐10. [MEDLINE: ] - PubMed
Evans 1997
    1. Evans AS, Kaslow RA (editors). Viral Infection of Humans: Epidemiology and Control. 4th Edition. New York: Plenum Press, 1997.
Falsey 2005
    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high‐risk adults. New England Journal of Medicine 2005;352(17):1749‐59. [MEDLINE: ] - PubMed
Fermi Paradox 2012
    1. Fermi Paradox. www.crystalinks.com/fermiparadox.html 2012 (accessed 12 July 2012).
Freiman 1978
    1. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. New England Journal of Medicine 1978;299(13):690‐4. [PUBMED: 355881] - PubMed
Gabriel 2012
    1. Gabriel SE, Normand SL. Getting the methods right ‐ the Foundation of Patient‐Centered Outcomes Research. New England Journal of Medicine 2012;367(9):787‐90. [DOI: 10.1056/NEJMp1207437] - DOI - PubMed
Glezen 2000
    1. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory infection on persons with chronic underlying conditions. JAMA 2000;283(4):499‐505. [MEDLINE: ] - PubMed
Goldsby 2000
    1. Goldsby R, Kingt T, Osborne B. Overview of the immune system. Kuby Immunology. 4th Edition. Vol. 3, New York, NY: WH Freeman Co, 2000.
Gonzales 2001
    1. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clinical Infectious Diseases 2001;33(6):757‐62. [MEDLINE: ] - PubMed
Gorczynski 2007
    1. Gorczynski R, Stanley J. Problem‐based immunology [Inmunología basaqda en la resolución de problemas]. Inmunología Basada en Problemas. Vol. 138, Madrid: Elsevier Saunders, 2007.
GRADEpro GDT 2014 [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version Accessed: October 15th, 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Gray 2007
    1. Gray GC, McCarthy T, Lebeck MG, Schnurr OP, Russell KL, Kajon AE, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004‐2006. Clinical Infectious Diseases 2007;45(9):1120‐31. [MEDLINE: ] - PMC - PubMed
Green 2002
    1. Green SB. Design of randomized trials. Epidemiologic Reviews 2002;24(1):4‐11. [PUBMED: 12119855] - PubMed
Grüber 2008
    1. Grüber C, Keil T, Kulig M, Roll S, Wahn U, Wahn V, MAS‐90 Study Group. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatric Allergy and Immunology 2008;9(6):505‐12. [PUBMED: 18167154] - PubMed
Gwaltney 1967
    1. Gwaltney JM, Hendley J, Simon G, Jordan WSJ. Rhinovirus infections in an industrial population II. Characteristics of illness and antibody response. JAMA 1967;202(6):494‐500. [PUBMED: 4293015] - PubMed
Gwaltney 1985
    1. Gwaltney JM. Virology and immunology of the common cold. Rhinology 1985;23(4):265‐71. [MEDLINE: ] - PubMed
Gwaltney 2000
    1. Gwaltney JM. The common cold. In: Mandell GL, Bennett JE, Dolin R editor(s). Principles and Practices of Infectious Diseases. 5th Edition. New York, NY: Churchill Livingstone, 2000:651‐6.
Hall 2001
    1. Hall CV. Respiratory syncytial virus and parainfluenza virus. New England Journal of Medicine 2001;344(25):1917‐28. [MEDLINE: ] - PubMed
Harrison 2008
    1. Fauci AS, Brownwald E, Kasper D, Hauser S, Longo D, Hameson L, et al. Harrison Principios de Medicina Interna. 17th Edition. McGraw Hill, 2008.
Heikkinen 2003
    1. Heikkinen T, Jarvinen A. The common cold. Lancet 2003;361(9351):51‐9. [MEDLINE: ] - PMC - PubMed
Henrickson 1994
    1. Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza viruses types 1 and 2 in young children. Clinical Infectious Diseases 1994;18(5):770‐9. [MEDLINE: ] - PubMed
Henrickson 2003
    1. Henrickson KJ. Parainfluenza viruses. Clinical Microbiology Reviews 2003;16(2):242‐64. [PUBMED: 12692097] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hussell 1998
    1. Hussell T, Georgiou A, Sparer T, Matthews S, Pala P, Openshaw P. Host genetic determinants of vaccine‐induced eosinophilia during RSV infection. Journal of Immunology 1998;161(11):6215‐22. [PUBMED: 9834108] - PubMed
Ioannidis 2004
    1. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. [PUBMED: 15545678] - PubMed
Ioannidis 2010
    1. Ioannidis JP. Meta‐research: the art of getting it wrong. Research Synthesis Methods 2010;1(3‐4):169‐84. [PUBMED: 26061464] - PubMed
Jackson 2008
    1. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high‐risk children. American Journal of Respiratory and Critical Care Medicine 2008;178(7):667‐72. [MEDLINE: ] - PMC - PubMed
Jefferson 2011
    1. Jefferson T, Mar CB, Dooley L, Ferroni E, Al‐Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD006207.pub4] - DOI - PMC - PubMed
Jefferson 2012
    1. Jefferson T, Rivetti A, Harnden A, Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD004879.pub4] - DOI - PubMed
Kahn 2003
    1. Kahn JS. Human metapneumovirus: a newly emerging respiratory pathogen. Current Opinion in Infection Diseases 2003;16(3):255‐8. [MEDLINE: ] - PubMed
Kang 2009
    1. Kang SM, Compans RW. Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Molecular Cell 2009;27(1):5‐14. [MEDLINE: ] - PMC - PubMed
Kirby 2002
    1. Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. Medical Journal of Australia 2002;177(5):256‐7. [PUBMED: 12197821] - PubMed
Krasinski 1985
    1. Krasinski K. Severe respiratory syncytial virus infection: clinical features, nosocomial acquisition and outcome. Pediatric Infectious Disease 1985;4(3):250‐7. [MEDLINE: ] - PubMed
Larson 1980
    1. Larson HE, Reed SE, Tyrrell DA. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. Journal of Medical Virology 1980;5(3):221‐9. [MEDLINE: ] - PMC - PubMed
Lau 2006
    1. Lau S, Woo P, Yip L, Tse H, Tesoi H, Ching V, et al. Coronavirus HKU1 and other coronavirus infection in Hong Kong. Journal of Clinical Microbiology 2006;44(6):2063‐71. [MEDLINE: ] - PMC - PubMed
Leder 2003
    1. Leder K, Sinclair MI, Mitakakis TZ, Hellard ME, Forbes A. A community‐based study of respiratory episodes in Melbourne, Australia. Australian and New Zealand Journal of Public Health 2003;27(4):399–404. [PUBMED: 14705301] - PubMed
Lemanske 2005
    1. Lemanske RF Jr, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. Journal of Allergy and Clinical Immunology 2005;116(3):571‐7. [MEDLINE: ] - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. [PUBMED: 9746022] - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ 2009;339:2535. - PMC - PubMed
Moher 2010
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [PUBMED: 20332511] - PMC - PubMed
Monto 1993
    1. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiology and Infection 1993;110(1):145‐60. [MEDLINE: ] - PMC - PubMed
Mäkelä 1998
    1. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. Journal of Clinical Microbiology 1998;36(2):539‐42. [MEDLINE: ] - PMC - PubMed
Nebeker 2004
    1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795‐801. [MEDLINE: ] - PubMed
Nelson 2000
    1. Kliegman R, Behrman RE, Jenson HB. Nelson Tratado de Pediatría. 16th Edition. McGraw Hill, 2000.
Nicholson 1997
    1. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective population based study of disease burden. BMJ 1997;315(7115):1060‐4. - PMC - PubMed
Nissen 2002
    1. Nissen MD, Siebert DJ, Mackay IM, Sloots TP, Withers SJ. Evidence of human metapneumovirus in Australian children. Medical Journal of Australia 2002;176(4):188. [MEDLINE: ] - PMC - PubMed
Palmemberg 2009
    1. Palmemberg AC, Spiro D, Kuzmickas R, Wang S, Djikeng A, Rathe JA, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009;324(5923):55‐9. [MEDLINE: ] - PMC - PubMed
Peltola 2008
    1. Peltola V, Waris M, Osterback R, Susi P, Hyypiä T, Ruuskanen O. Clinical effects of rhinovirus infections. Journal of Clinical Virology 2008;43(4):411‐4. [MEDLINE: ] - PubMed
Pichichero 2009
    1. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis?. Pediatrics 2009;124(6):1633‐41. [MEDLINE: ] - PubMed
Plotkin 2008
    1. Plotkin SA. Vaccines: correlates of vaccine‐induced immunity. Clinical Infectious Diseases 2008;47(3):401‐9. [MEDLINE: ] - PubMed
Poland 2009
    1. Poland G, Barry MA. Common cold, uncommon variation. New England Journal of Medicine 2009;360(21):2245‐6. [MEDLINE: ] - PubMed
Regamey 2008
    1. Regamey N, Kaiser L. Rhinovirus infections in infants: is respiratory syncytial virus ready for the challenge?. European Respiratory Journal 2008;32(2):249‐51. [MEDLINE: ] - PubMed
Ren 2017
    1. Ren L, Yang D, Ren X, Li M, Mu X, Wang Q, et al. Genotyping of human rhinovirus in adult patients with acute respiratory infections identified predominant infections of genotype A21. Scientific Reports 2017;7:41601. [PUBMED: 28128353] - PMC - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rey‐Jurado 2017
    1. Rey‐Jurado E, Kalergis AM. Immunological features of respiratory syncytial virus‐caused pneumonia ‐ implications for vaccine design. International Journal of Molecular Sciences 2017;18(3):556. [DOI: 10.3390/ijms18030556] - DOI - PMC - PubMed
Risnes 2005
    1. Risnes KR, Radtke A, Nordbø SA, Grammeltvedt AT, Døllner H. Human metapneumovirus ‐ occurrence and clinical significance. Tidsskrift for den Norske Lægeforening 2005;20:2769‐72. [MEDLINE: ] - PubMed
Roitt 2004
    1. Roitt I, Delves P. Glossary. Essential Immunology. 10th Edition. Vol. 466, Blackwell, 2004.
Roxas 2007
    1. Roxas M, Jurenka J. Colds and influenza: a review of diagnosis and conventional, botanical and nutritional considerations. Alternative Medicine Review 2007;12(1):25‐48. [MEDLINE: ] - PubMed
Russell 2006
    1. Russell KL, Hawksworth AW, Ryan MA, Strickler J, Irvine M, Hansen CJ, et al. Vaccine‐preventable adenoviral respiratory illness in US military recruits, 1999‐2004. Vaccine 2006;24(15):2835‐42. [MEDLINE: ] - PMC - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [PUBMED: 7823387] - PubMed
Thompson 2003
    1. Thompson WW. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289(2):179‐86. [MEDLINE: ] - PubMed
Tobin 2008
    1. Tobin G, Trujillo JD, Bushnell R, Lin G, Chaudhuri RA, Largo J, et al. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008;26(49):6189‐99. - PubMed
Wat 2004
    1. Wat D. The common cold: a review of the literature. European Journal of Internal Medicine 2004;15(2):79‐88. [MEDLINE: ] - PMC - PubMed

References to other published versions of this review

Felix 2011
    1. Felix ML, Guerra CV, Hinojosa MA, Cabezas CI, Hidalgo R, Samaniego DH, et al. Vaccines for the common cold. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD002190.pub3] - DOI
Simancas‐Racines 2013
    1. Simancas‐Racines D, Guerra CV, Hidalgo R. Vaccines for the common cold. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD002190.pub4] - DOI - PubMed

Publication types

MeSH terms